The Genetics Policy Institute (GPI) and the Regenerative Medicine Foundation (RMF) will merge, the leaders of both organizations announced at the opening session of the 10th Annual World Stem Cell Summit (WSCS).
The three-dimensional biology company Organovo Holdings Inc. announced the full commercial...
Real-time qPCR is one of the most ubiquitous laboratory techniques in modern life sciences,...
Patience may be a virtue. But in a lab that’s bustling with scientists conducting meaningful biological research, excessive waiting can be downright frustrating. Such was the case leading up to 2012, when researchers at The University of Chicago Flow Cytometry Core Facility— known as UCFlow— would routinely wait as long as 16 days to be able to sort cells.
The Federal Trade Commission said Friday it has approved Thermo Fisher Scientific Inc.'s $13.6 billion acquisition of Life Technologies Corp., as long as the scientific instrument maker sells some assets to a unit of General Electric Co.
The Food and Drug Administration has cleared a first-of-a-kind blood test that can help predict intellectual disabilities in infants by analyzing their genetic code. The laboratory test from Affymetrix detects variations in patients' chromosomes that are linked to Down syndrome, DiGeorge syndrome and other developmental disorders.
Johnson & Johnson has been offered $4.15 billion by The Carlyle Group for its Ortho-Clinical Diagnostics business, a year after J&J began reviewing strategic options for the blood-testing unit as part of a routine pruning of its extensive family of businesses. J&J has until March 31 to decide whether to accept the offer.
Biotech drugmaker Amgen and Illumina, a maker of genetic testing equipment, said Wednesday they are developing a test that will identify patients who might be helped by Amgen's colon cancer drug Vectibix. Vectibix is approved as a treatment for colorectal cancer that has spread and hasn't rresponded to chemotherapy.
Thermo Fisher Scientific announced that it has signed an agreement to sell its cell culture (sera and media), gene modulation and magnetic beads businesses to GE Healthcare, a unit of General Electric Company, for approximately $1.06 billion.
With so many new innovations emerging in genomics research, the evolving technology of next generation sequencing (NGS) is becoming an increasingly powerful tool, with researchers now able to simultaneously screen for thousands of disease-linked variants in a single individual.
Sartorius successfully completed its acquisition of UK company TAP Biosystems Group plc. The cash offer made through Sartorius’ wholly owned subsidiary Sartorius Stedim Biotech valued TAP Biosystems Group plc at approximately €33 million and had been approved by TAP Biosystems’ shareholders on November 21, 2013.
Definiens recently released results from an industry survey on the drivers of automated image analysis adoption and predictions on the future of digital pathology.
Life Technologies Receives 2013 Presidential Green Chemistry Challenge Award by Environmental Protection AgencyDecember 11, 2013 1:30 pm | by Life Technologies | News | Comments
Life Technologies Corporation (NASDAQ: LIFE) announced today that the company's Austin manufacturing facility has received the 2013 Presidential Green Chemistry Challenge Award in the category of Greener Synthetic Pathways.
Accelrys, Inc. today announced that it has acquired Ireland-based QUMAS, a leading global provider of Cloud-based and on-premises enterprise compliance software supporting regulatory and quality operations in life sciences and other highly regulated industries.
The New York Stem Cell Foundation (NYSCF) Research Institute and PersonalGenomes.org announced a partnership to identify genetic and environmental contributions to trait and disease development.
ImmunoChemistry Technologies (ICT) has changed ownership and is now majority women-owned. The company will continue to develop new products to help researchers discover new treatments and drugs for cancer and other diseases affecting both animals and humans.
Roche announced plans to invest 800 million Swiss francs within its global manufacturing network to increase production capabilities for its biologic medicines over the next five years. The investment will be spread across sites in Penzberg (Germany), Basel (Switzerland), as well as Vacaville and Oceanside (USA). Approximately 500 new jobs are expected to be created in conjunction with the facility expansions.
Sartorius Stedim Biotech today made a cash offer to acquire the UK company TAP Biosystems Group plc (TAP Biosystems), through its wholly owned subsidiary Sartorius Stedim Biotech GmbH. The proposed transaction, which is subject to customary closing conditions, including the approval of TAP’s shareholders, values the equity of TAP Biosystems at approximately €33 million.
Roche and the Medicines Patent Pool Sign Agreement to Increase Access to Medicines to Treat CMV infection in HIV-patients, a major cause of BlindnessAugust 5, 2013 1:00 am | by Roche | News | Comments
The Medicines Patent Pool and healthcare company Roche announce an agreement to increase access to Valcyte (valganciclovir), a key medicine to treat cytomegalovirus (CMV). CMV is a viral infection that can result in loss of vision and greater risk of death in people living with HIV. This infection affects around 1 in 10 people living with HIV in low- and middle-income countries.
Analyses of protein structure and function depend on the reliable production of pure, functionally active protein, but traditional centrifugation-based affinity purification presents challenges. Batch processing of resins in microcentrifuge tubes is subject to sample loss during aspiration, and spin columns have a limited volume capacity that makes protocols tedious and requires multiple spin cycles.
Harvard Bioscience Inc., a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today reported unaudited financial results for the three and six months ended June 30, 2013.
Thermo Fisher Scientific Showcases Technologies to Improve Accuracy and Productivity in the Clinical LaboratoryJuly 30, 2013 8:31 am | by Thermo Fisher Scientific | News | Comments
Thermo Fisher Scientific Inc. showcased its comprehensive offering of specialty diagnostics products and analytical instruments designed to improve accuracy and productivity in clinical applications. The Thermo Scientific solutions are on display in booth 5140 during the Clinical Lab Expo at the American Association for Clinical Chemistry (AACC) conference.
Life Technologies Corporation announced that it has signed a five-year agreement with the Food and Drug Administration (FDA) to accelerate and advance food safety testing of E. coli and Salmonella, two foodborne contaminants commonly associated with outbreaks and/or recalls.
Life Technologies Corporation announced the expansion of its global food safety portfolio with the worldwide distribution of the RT-qPCR assays for the detection of Norovirus GI and Norovirus GII, Hepatitis A, and the Mengovirus Extraction Control Kit by CEERAM (the European Centre for Expertise and Research on Microbial Agents).
Group sales 5 percent higher at 23.3 billion Swiss francs; Core EPS 12 percent higher at 7.58 Swiss francs; net income rose to 6 billion Swiss francs; Pharmaceuticals sales rose 6 percent due to cancer medicines and Actemra; Diagnostics sales increased 3 percent driven by Professional Diagnostics, offset by decline in Diabetes Care.
Accelrys, Inc. announced it will report financial results for its 2013 second quarter ended June 30, 2013 after the NASDAQ Market closes on Wednesday, July 31, 2013. The Company will conduct a conference call and an audio webcast at 2 p.m. PT (5 p.m. ET) on the same day.
Roche today announced positive results from the phase III CLL11 study. At a pre-planned interim analysis, an independent data monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to MabThera/Rituxan plus chlorambucil.
Life Technologies Corporation announced that it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission regarding Thermo Fisher Scientific Inc.'s (NYSE: TMO) pending acquisition of the Company and has set the date for a special meeting of stockholders to approve the transaction.
- Page 1